Increased activity of MMP-2 in hypertensive obese children is associated with hypoadiponectinemia

Obesity

Volumn 23, Issue 1, 2015, Pages 177-182

  Belo, Vanessa A ^a   Lacchini, Riccardo ^a   Miranda, Josiane A ^b   Lanna, Carla M M ^c   Souza Costa, Debora C ^c   Tanus Santos, Jose E ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; GELATINASE A; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRIACYLGLYCEROL; MMP2 PROTEIN, HUMAN; TIMP2 PROTEIN, HUMAN;

AGE; ARTICLE; BODY MASS; CHILD; CHILDHOOD OBESITY; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOADIPONECTINEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MULTIPLE LINEAR REGRESSION ANALYSIS; PATHOGENESIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO; ZYMOGRAPHY; ADOLESCENT; BLOOD; CASE CONTROL STUDY; COMPLICATION; DEFICIENCY; INBORN ERROR OF METABOLISM; METABOLISM; REGRESSION ANALYSIS;

ADIPONECTIN; ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; HYPERTENSION; MALE; MATRIX METALLOPROTEINASE 2; METABOLISM, INBORN ERRORS; PEDIATRIC OBESITY; REGRESSION ANALYSIS; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 84928233529     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20939     Document Type: Article

References (40)

1. Cote AT, Harris KC, Panagiotopoulos C, et al. Childhood obesity and cardiovascular dysfunction. J Am Coll Cardiol 2013; 62: 1309.
2. Prendergast C, Gidding SS,. Cardiovascular risk in children and adolescents with type 2 diabetes mellitus. Curr Diab Rep 2014; 14: 454.
3. Van Gaal LF, Mertens IL, De Block CE,. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880.
4. Barness LA, Opitz JM, Gilbert-Barness E,. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A 2007; 143A: 3016-3034.
5. Kadowaki T, Yamauchi T,. Adiponectin and adiponectin receptors. Endocr Rev 2005; 26: 439-451.
6. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83.
7. Stefan N, Bunt JC, Salbe AD, et al. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab 2002; 87: 4652-4656.
8. Belo VA, Souza-Costa DC, Lachinni R, et al. Adiponectin associates positively with nitrite levels in children and adolescents. Int J Obes 2013; 37: 740.
9. Kumada M, Kihara S, Sumitsuji S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89.
10. Pischon T, Girman CJ, Hotamisligil GS, et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737.
11. Adamczak M, Wiecek A, Funahashi T, et al. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2003; 16: 72-75.
12. Ouchi N, Ohishi M, Kihara S, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
13. Chen H, Montagnani M, Funahashi T, et al. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003; 278: 45021-45026.
14. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
15. Castro MM, Rizzi E, Figueiredo-Lopes L, et al. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 2008; 198: 320-331.
16. Rizzi E, Castro MM, Prado CM, et al. Matrix metalloproteinase inhibition improves cardiac dysfunction and remodeling in 2-kidney, 1-clip hypertension. J Card Fail 2010; 16: 599-608.
17. Essick EE, Ouchi N, Wilson RM, et al. Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol 2011; 301: H984-H993.
18. Guimaraes DA, Rizzi E, Ceron CS, et al. Doxycycline dose-dependently inhibits MMP-2-mediated vascular changes in 2K1C hypertension. Basic Clin Pharmacol Toxicol 2011; 108: 318-325.
19. Antonio RC, Ceron CS, Rizzi E, et al. Antioxidant effect of doxycycline decreases MMP activity and blood pressure in SHR. Mol Cell Biochem 2014; 386: 99-105.
20. Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 2006; 13: 227-231.
21. Berg G, Miksztowicz V, Schreier L,. Metalloproteinases in metabolic syndrome. Clin Chim Acta 2011; 412: 1731-1739.
22. Fernandez-Patron C, Radomski MW, Davidge ST,. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 1999; 85: 906-911.
23. Belo VA, Luizon MR, Carneiro PC, et al. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep 2013; 40: 2697-2704.
24. Glowinska-Olszewska B, Urban M, Florys B,. Selected matrix metalloproteinases (MMP-2, MMP-9) in obese children and adolescents. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw 2006; 12: 179-183.
25. Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, et al. CDC growth charts: United States. Adv Data 2000; 314: 1-27.
26. Update on the 1987 task force report on high blood pressure in children and adolescents: a working group report from the National High Blood Pressure Education Program. National high blood pressure education program working group on hypertension control in children and adolescents. Pediatrics 1996; 98 (4, Part 1): 649-658.
27. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
28. Gerlach RF, Demacq C, Jung K, et al. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin Biochem 2007; 40: 119-123.
29. Gerlach RF, Uzuelli JA, Souza-Tarla CD, et al. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal Biochem 2005; 344: 147-149.
30. Yasmin C, McEniery M, Wallace S, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 372.
31. Marchesi C, Dentali F, Nicolini E, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens 2012; 30: 3-16.
32. Zervoudaki A, Economou E, Pitsavos C, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and -9 in essential hypertension. Am J Hypertens 2004; 17: 273-276.
33. Ahmed SH, Clark LL, Pennington WR, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006; 113: 2089-2096.
34. Fontana V, Silva PS, Belo VA, et al. Consistent alterations of circulating matrix metalloproteinases levels in untreated hypertensives and in spontaneously hypertensive rats: a relevant pharmacological target. Basic Clin Pharmacol Toxicol 2011; 109: 130-137.
35. Nagase H, Visse R, Murphy G,. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
36. English JL, Kassiri Z, Koskivirta I, et al. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006; 281: 10337-10346.
37. Belo VA, Souza-Costa DC, Lana CM, et al. Assessment of matrix metalloproteinase (MMP)-2, MMP-8, MMP-9, and their inhibitors, the tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in obese children and adolescents. Clin Biochem 2009; 42: 984-990.
38. Madec S, Chiarugi M, Santini E, et al. Pattern of expression of inflammatory markers in adipose tissue of untreated hypertensive patients. J Hypertens 2010; 28: 1459-1465.
39. Brew K, Nagase H,. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 2010; 1803: 55-71.
40. Kosmala W, Plaksej R, Przewlocka-Kosmala M, et al. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function. Int J Obes (Lond) 2008; 32: 763-771.